regeneron pharmaceuticals semaglutide announced on January 30, 2026, that its experimental obesity drug candidate delivers significant Prolific' Regeneron won't stop with

While individual patients may experience blood pressure fluctuations for various reasons during treatment (including dehydration, medication changes, pain, or stress), the preponderance of evidence indicates that semaglutide typically has neutral-to-beneficial effects on blood pressure control

Ketamine, a dissociative anesthetic, works along the glutamate pathway and has shown promise as a potential treatment for severe depression in small doses.80 In nootropic supplements, caffeine, cocoa, theobromine, and L-theanine may influence glutamate

Effects of Dichrostachys glomerata and Cissus quadrangularis extracts on GLP-1 secretion and DPP-4 activity in overweight and obese individuals: A randomized controlled trial

However, the trio all reported reduced motivation, emotional flatness, or loss of interest in exercise and previously enjoyable activities despite successful weight loss, write the researchers

Choosing the Right Program Finding the right weight loss program is essential for success

Hunter explained how Alzheimers disease begins with amyloid plaques and explained that microglia play a role in the steps that lead to brain cells dying. The doctor also said that different trials are just to see how well GLP-1 drugs can help treat Alzheimers disease and that the drug that is closest to FDA [Food and Drug Administration] approval is semaglutide. Hunter expected that UTHealths own EVOKE trial will announce results on the use of semaglutide for Alzheimers in the fall of 2025